Abstract
Background: The study assessed the efficacy and tolerability of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine in the treatment of pathologic gambling (PG).
Methods: A 16-week randomized double-blind crossover design insured that each subject received 8 weeks of fluvoxamine and 8 weeks of a placebo. Fifteen patients entered and 10 subjects, all male, completed the study.
Results: Fluvoxamine resulted in a significantly greater percent improvement in overall gambling severity on the PG Clinical Global Impression (PG-CGI) scale. There was a significant drug effect on gambling urge and behavior as measured by the PG modification of the Yale–Brown Obsessive Compulsive Scale and PG-CGI scale improvement scores; however, there was a significant interaction of drug effect with the order of administration of drug and placebo. Post hoc analysis, treating each phase as a separate trial, demonstrated a significant difference between fluvoxamine and the placebo in the second phase of the trial but not in the first. Fluvoxamine side effects were of only mild intensity and consistent with SSRI treatment and were not associated with early withdrawal from the study.
Conclusions: These findings suggest that fluvoxamine is well tolerated and may be effective in the treatment of PG in an acute trial, and that an early placebo effect in PG treatment appears to diminish over time. To confirm this finding and to determine whether improvement persists over an extended period of time, a longer duration parallel-design trial with long-term maintenance follow-up should be conducted in a larger and more diverse PG population.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
-
Compulsive buying.J Clin Psychiatry. 1996; 57: 50-55
-
Low platelet MAO activity in pathological gambling.Acta Psychiatr Scand. 1994; 90: 427-431
-
Diagnosis, neurobiology, and treatment of pathological gambling.J Clin Psychiatry. 1996; 57: 80-84
- Obsessive-Compulsive Related Disorders. American Psychiatric Press, Washington, DC1993
-
Short-term single-blind fluvoxamine treatment of pathological gambling.Am J Psychiatry. 1998; 155: 1781-1783
-
Cognitive treatment of pathological gamblers.Behav Res Ther. 1998; 36: 1111-1119
-
The South Oaks Gambling Screen (SOGS).Am J Psychiatry. 1987; 144: 1184-1188
-
Gambling and pathological gambling among college students.Addict Behav. 1991; 16: 517-527
-
Gambling and pathological gambling among high school students.Addict Behav. 1987; 12: 129-135
-
Access to gambling opportunities and compulsive gambling.Int J Addict. 1994; 29: 1611-1616
-
Serotonin and gambling dependence.Hum Psychopharmacol. 1991; 6: S9-S12
- National Council on Problem Gambling Research and Public Policy Committees. National Council on Problem Gambling, Columbia, MD1997
-
Estimating the prevalence of adolescent gambling.J Gambling Stud. 1996; 12: 193-214
-
An outcome study of Gambler’s Anonymous.Br J Psychiatry. 1988; 152: 284-288
-
The prevalence and demographics of pathological gamblers.Am J Pub Health. 1994; 84: 237-241
Article info
Publication history
Accepted: December 17, 1999
Received in revised form: December 7, 1999
Received: August 30, 1999
Identification
Copyright
© 2000 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
